Health Economics›Acute lymphoblastic leukemia infant›Induction

Induction

Acute lymphoblastic leukemia infant · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cytarabine, Daunorubicin, L-Asparaginase, Vincristine, Dexamethasone Variant #01 Partial	KMT2A	R 8 407	28d	—	—	~1	~R 8 407 indirect	—

1 of 1 regimen shown